Table 5.
Multivariate Logistic Regression Analysis of Factors Important in Early (Within 5 Days) and Late (> 5 Days) Mortality
| Effect | Early Mortality | Late Mortality | ||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Risk score (per additional score) | 1.024* | 1.014–1.033 | 1.025* | 1.018–1.033 |
| Age (per additional year) | 1.044* | 1.016–1.074 | 1.028* | 1.009–1.047 |
| Site | ||||
| A vs E | 0.581 | 0.185–1.817 | 0.863 | 0.315–2.361 |
| B vs E | 1.594 | 0.443–5.735 | 1.089 | 0.295–9.014 |
| C vs E | 3.157* | 1.241–8.032 | 2.924* | 1.265–6.758 |
| D vs E | 0.672 | 0.254–1.755 | 1.533 | 0.690–3.494 |
| F vs E | 1.370 | 0.523–3.586 | 1.597 | 0.689–3.703 |
| Functional status | ||||
| Walking with assistance vs walking unassisted | 1.810 | 0.967–3.388 | 1.229 | 0.771–1.959 |
| Wheelchair vs walking unassisted | 3.313* | 1.457–7.533 | 1.921* | 1.037–3.558 |
| Bedridden vs walking unassisted | 8.287* | 2.877–23.866 | 3.657* | 1.456–9.146 |
| Consult—infectious diseases/respirology | 1.965 | 0.984–3.923 | 2.468* | 1.559–3.905 |
| Pathway partial vs no use | 0.453* | 0.233–0.882 | 1.459 | 0.760–2.873 |
| Pathway completely used | 0.443* | 0.216–0.909 | 1.184 | 0.596–2.354 |
| Levofloxacin vs other | 0.643 | 0.380–1.090 | 0.433* | 0.289–0.647 |
| Cefuroxime/azithromycin vs other | 0.976 | 0.301–3.160 | 0.223* | 0.051–0.975 |
| Lymphocytes < 1 yes vs no | 2.047* | 1.206–3.477 | 1.051 | 0.716–0.975 |
| Potassium > 5.0 vs normal | 2.759* | 1.411–5.397 | 0.888 | 0.950–1.929 |
| Substance abuse yes vs no | 2.795* | 1.091–7.161 | ||
*
Statistically significant.